Devonian Health Group Inc. (
TSX: V.GSD,
Forum) today announced its first exclusive marketing and distribution agreement for Purgenesis™ distribution in Canada. This is the Company’s proprietary anti-aging treatment, part of a unique portfolio of botanical prescription drugs and cosmeceutical products. The agreement is with Altius Healthcare Inc.
This exclusive agreement includes up-front payment for each treatment and a 25% royalty based on total sales. Altius has planned a product launch for Q4 2017. Purgenesis™ was
recently recognized by the Canadian Dermatology Association through its Skin Health Program™, and it will be made available in Canada exclusively via certified dermatologists.
The product has three components: a day cream, a night cream, and an eye cream. The primary active ingredient is R-Spinasome®, a biological complex with powerful antioxidant properties. Previous product testing has delivered superior results versus existing products already on the market. Further information can be found
here.
The Company was recently in the news earlier this month when it announced it would be presenting at the
18th Global Chinese Financial Conference (GCFC).
FULL DISCLOSURE: Devonian Health Group Inc. is a paid client of Stockhouse Publishing.